Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.2283
- Book/Share 15.6573
- PB 1.6332
- Debt/Equity 0.6967
- CurrentRatio 1.1584
- ROIC 0.1119
- MktCap 144867826740.0
- FreeCF/Share 2.1879
- PFCF 11.6472
- PE 13.5024
- Debt/Assets 0.2998
- DivYield 0.0671
- ROE 0.1194
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
This 6.75%-Yielding Dividend Stock Can Gain 33%
Published: October 01, 2025 by: 24/7 Wall Street
Sentiment: Positive
Pfizer (NYSE:PFE) shares are finally starting to attract attention after gaining close to 7% in a single trading session on news that it's reached a pricing deal with the Trump administration.
Read More
Pfizer Drug-Pricing Deal: More Upside For PFE Stock?
Published: October 01, 2025 by: Forbes
Sentiment: Positive
Pfizer stock (NYSE: PFE) offers a compelling investment opportunity at its current price of around $25, supported by attractive valuations and recent policy changes that may present further upside potential.
Read More
Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug
Published: September 30, 2025 by: CNBC
Sentiment: Positive
Metsera released data from mid-stage trials on its lead obesity drug candidate, while a high stakes Medicare open enrollment approaches.
Read More
3 Pharma Stocks Getting an Intraday Trump Bump
Published: September 30, 2025 by: Schaeffers Research
Sentiment: Positive
Pharmaceutical stocks are enjoying tailwinds today, after President Donald Trump announced the launch of a direct-to-consumer website dubbed "TrumpRX.
Read More
Pfizer found a way to boost its ailing stock — agree with Trump on drug pricing
Published: September 30, 2025 by: Market Watch
Sentiment: Positive
Pfizer's stock surged after CEO Albert Bourla announces an agreement with the Trump administration aimed at lowering drug prices in the U.S. and removing tariff uncertainty.
Read More
What Pfizer's lower drug price agreement may mean for the company
Published: September 30, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's Angelica Peebles joins "The Exchange" to detail Pfizer's agreement with the Trump administration to voluntarily sell its medications at lower prices in the United States.
Read More
Pfizer CEO: 'The big winner of this deal clearly will be the American patient'
Published: September 30, 2025 by: CNBC Television
Sentiment: Positive
Pfizer CEO Albert Bourla, speaking in the Oval Office on Tuesday about the company's deal to lower drug prices, said the winner of the deal will "clearly will be the American patient." Bourla said the company satisfied all four of the requests President Trump outlined.
Read More
Top Stock Movers Now: Spotify, Pfizer, CoreWeave, Lamb Weston, and More
Published: September 30, 2025 by: Investopedia
Sentiment: Negative
Major U.S. equities indexes edged lower Tuesday afternoon, as a potential government shutdown loomed. The Dow, S&P 500, and Nasdaq were all slightly lower.
Read More
US drugmakers rise after Trump announces Pfizer price cuts, promises more deals
Published: September 30, 2025 by: Reuters
Sentiment: Positive
Shares of Pfizer rose about 5% after U.S. President Donald Trump said on Tuesday the drugmaker will cut the price on all of its prescription drugs sold to the Medicaid insurance program and will introduce all new prescription drugs at a "most favored nation" price.
Read More
Trump: Pfizer agreed to heavily discount prices for some current drugs
Published: September 30, 2025 by: CNBC Television
Sentiment: Positive
President Donald Trump speaks from the Oval Office to announce that Pfizer has agreed to take measures to lower U.S. drug prices, including selling its existing drugs to Medicaid patients at the lowest price offered in other developed nations.
Read More
Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients
Published: September 30, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced a historic agreement with the Trump Administration that will ensure U.S. patients pay lower prices for their prescription medicines while strengthening America's role as the global leader in biopharmaceutical innovation. In response to the four points covered in the President's July 31st letter, Pfizer has voluntarily agreed to implement measures designed to ensure Americans receive comparable drug prices to those available in o.
Read More
7 Ideal "Safer" Dividend Buys From 61 September Graham Value All-Stars (GVAS)
Published: September 30, 2025 by: Seeking Alpha
Sentiment: Positive
The article analyzes Large Cap Value (GASV) stocks using YCharts' Value Score and the Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Seven of fourteen 'safer' lowest-priced GASV Dogs—ET, MPLX, YRD, VZ, BMY, BBVA, and MFC—are highlighted as buyable for September 2025. Top ten GASV stocks are projected by analysts to deliver average net gains of 26.84% by September 2026, with Energy Transfer (ET) leading at 35.43%.
Read More
Pfizer first to offer 'major discounts' to US customers via govt website, says Trump
Published: September 30, 2025 by: Proactive Investors
Sentiment: Positive
Pfizer Inc (NYSE:PFE, ETR:PFE) shares jumped 3.5% after Donald Trump said the drugmaker would be the first company offering lower prices on its prescription drugs. Under a new agreement with the White House, the company will offer "major discounts" under the "most favoured nation" drug pricing order established earlier this year.
Read More
Trump, Pfizer to announce agreement to lower Medicaid drug prices
Published: September 30, 2025 by: CNBC Television
Sentiment: Positive
President Donald Trump on Tuesday will announce an agreement with Pfizer to voluntarily sell its medications for less, as his administration pushes to link U.S. drug prices to cheaper ones abroad, CNBC's Angelica Peebles reports.
Read More
President Trump to announce drug-pricing deal with Pfizer
Published: September 30, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Eamon Javers joins 'Squawk on the Street' with the latest news.
Read More
Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.
Published: September 30, 2025 by: Barrons
Sentiment: Positive
Pfizer said last week it would pay $47.50 per share for Metsera, and an extra $22.50 per share if its drugs hit certain milestones.
Read More
Trump, Pfizer to announce agreement to lower drug prices
Published: September 30, 2025 by: CNBC
Sentiment: Positive
President Donald Trump will announce an agreement with Pfizer to voluntarily sell its medications at lower prices, as his administration pushes to link U.S. drug prices to the cheaper prices paid abroad. In this article PFE
Read More
White House to Announce ‘TrumpRx' Drug-Buying Website, and Deal With Pfizer
Published: September 30, 2025 by: WSJ
Sentiment: Positive
President Trump is expected to unveil the measures with Pfizer's CEO on Tuesday
Read More
Trump to announce deal with Pfizer to sell drugs at lower prices, Washington Post reports
Published: September 30, 2025 by: Reuters
Sentiment: Positive
U.S. President Donald Trump will announce an agreement with Pfizer on Tuesday to voluntarily sell the company's medications through Medicaid at lower prices, the Washington Post reported on Tuesday, citing sources.
Read More
Pfizer Is Likely To Pass The Drug Import Tariff Stress Test
Published: September 29, 2025 by: Seeking Alpha
Sentiment: Positive
President Trump's new 100% tariff on imported drugs creates a major new risk for the pharma sector. While competitors announce flashy, multi-billion-dollar U.S. investment plans, Pfizer appears vague in comparison. We argue this perception is misleading and overlooks the company's core strategic advantage. A deep dive into Pfizer's existing manufacturing footprint and management's plan to onshore new technologies reveals a powerful and underappreciated case for a tariff exemption.
Read More
3 Of My Favorite Biotech Stocks Under $10
Published: September 29, 2025 by: Seeking Alpha
Sentiment: Positive
Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited for consistent covered call trades. Covered call strategies offer downside protection in the underperforming, high-beta biotech sector, supporting a rinse, wash, and repeat approach.
Read More
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Hearing Against Pfizer Set For 29 September In Contraceptive ‘Depo-Provera' Multidistrict Litigation Overseen By Levin Papantonio
Published: September 25, 2025 by: Business Wire
Sentiment: Neutral
PENSACOLA, Fla.--(BUSINESS WIRE)--A hearing in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Monday, 29 September at 9:00am CT in the United States Courthouse in Pensacola, Florida. The hearing will address oral arguments from the plaintiffs and defendants concerning the issue of pre-emption. The pre-emption defence is common in drug litigation. It involves the drug manufacturer arguing that they cannot be sued for failure to warn under state law, because chang.
Read More
Pfizer: Invest For The Yield, Not The Weight-Loss Drug Chase
Published: September 25, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer Inc. is acquiring Metsera for up to $7.2 billion, aiming to enter the weight-loss drug market despite late-stage entry and no ongoing Phase 3 trials. PFE's acquisition targets GLP-1-based obesity drugs but faces stiff competition from established players like Eli Lilly and Novo Nordisk and promising biotechs like Viking Therapeutics. The stock offers a compelling 7% dividend yield, supported by cost-saving initiatives and stable oncology/vaccine growth, despite declining Covid vaccine sales.
Read More
Can PFE Successfully Return to the Obesity Space With Metsera Buyout?
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer strikes a $4.9B deal for Metsera, adding obesity drug candidates to its pipeline after scrapping danuglipron.
Read More
Pfizer's Metsera buy raises competitive heat for Novo Nordisk
Published: September 23, 2025 by: Proactive Investors
Sentiment: Negative
UBS has warned that Pfizer Inc's (NYSE:PFE, ETR:PFE) $7.3 billion acquisition of Metsera will sharpen competition for Novo Nordisk (NYSE:NVO) in the fast-growing obesity drug market, particularly towards the end of the decade. The bank kept its 'neutral' rating on Novo shares with a DKr340 price target, implying 12.5% downside from the current level.
Read More
Pfizer bets $7.3 billion on obesity drugs with Metsera buy
Published: September 22, 2025 by: Fast Company
Sentiment: Positive
Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it's acquiring Metsera, and its portfolio of four medications for obesity and cardiometabolic diseases, in a deal valued at as much as $7.3 billion.
Read More
Pfizer Inc. (PFE) M&A Call Transcript
Published: September 22, 2025 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. (NYSE:PFE ) M&A Call September 22, 2025 8:00 AM EDT Company Participants Francesca DeMartino - Chief Investor Relations Officer Chris Boshoff - Chief Scientific Officer and President of Research & Development Andrew Baum - Chief Strategy & Innovation Officer, Executive VP Jim List Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division David Risinger - Leerink Partners LLC, Research Division Evan Seigerman - BMO Capital Markets Equity Research Umer Raffat - Evercore ISI Institutional Equities, Research Division Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Christopher Schott - JPMorgan Chase & Co, …
Read More
Johnson Fistel Investigates Fairness of Proposed Sale of Metsera
Published: September 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. (NYSE: PFE).
Read More
Pfizer Stock Higher on Multi-Billion Dollar Metsera Buyout
Published: September 22, 2025 by: Schaeffers Research
Sentiment: Positive
Pfizer Inc (NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after the pharma giant revealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000